Tamoxifen to Treat Barrett's Metaplasia

Status Terminated

Clinical Trial Summary

Treat Barrett's esophagus (BE) patients with tamoxifen to Barrett's metaplasia as measured by changes in Barrett's esophagus appearance by endoscopy and histology as well as changes in SOX2 and CDX2.

Clinical Trial Description

Treat Barrett's esophagus (BE) patients with tamoxifen to determine the effects on Barrett's metaplasia as measured by changes in Barrett's esophagus appearance by endoscopy and histology. Tamoxifen treatment may induce SOX2 expression, decrease CDX2 and promote esophageal stem cell activity, leading to regression of Barrett's metaplasia. To test this hypothesis, we will conduct a prospective, pilot study where patients with BE, without high grade dysplasia, are treated with tamoxifen and assessed for changes in the appearance of their BE by endoscopy and histology as well as changes in the SOX2/CDX2 ratio indicative of an improvement in BE metaplasia ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02089386
Study type	Interventional
Source	Washington University School of Medicine
Contact
Status	Terminated
Phase	Early Phase 1
Start date	July 9, 2014
Completion date	June 21, 2016

View Details